---
title: Assess Parkinson symptoms in Italian
nct_id: NCT07316751
status: RECRUITING
sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07316751"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07316751"
last_fetched: "2026-05-10T14:08:21.616Z"
source: "Parkinson's Pathways (curated)"
---
# Assess Parkinson symptoms in Italian

**Goal (in five words):** Assess Parkinson symptoms in Italian

**Official Title:** Italian Translation and Validation of the GIDS-PD Scale for Parkinson's Disease

**Trial ID:** [NCT07316751](https://clinicaltrials.gov/study/NCT07316751)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- **Target Enrollment:** 190 participants
- **Start Date:** 2025-10-08
- **Completion Date:** 2028-11
- **Conditions:** PARKINSON DISEASE (Disorder), Parkinson Disease

## Summary For Families

The goal is to produce and validate an Italian version of the GIDS-PD scale so clinicians and researchers have a reliable tool to measure Parkinson's symptom severity and how those symptoms affect daily life in Italian-speaking patients. The team will translate the questionnaire and then test it in about 190 people, checking that the questions are clear, consistent, and accurately reflect patients' symptoms and function; no drug or device is given because it is an observational validation. Adults 18 and older with Parkinson's diagnosed by the MDS criteria who understand Italian and can give consent are eligible, while people in the terminal phase, with significant cognitive impairment, or with non-PD parkinsonism are excluded.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Age ≥18 years;
* Diagnosis of PD according to the Movement Disorder Society (MDS) diagnostic criteria (Postuma RB et al., 2015);
* Italian-native patients or patients that understand Italian correctly at least;
* Participants mentally and physically able to understand and sign the informed consent form.

Exclusion Criteria:

* Persons in the terminal phase of disease;
* Persons with clinically relevant cognitive impairment;
* Persons diagnosed with Parkinsonism other than PD.
```

## Locations (5)

- Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy _(42.7824, 12.5984)_
  - Roberto Eleopra, MD — (CONTACT) — + 39 02.2394 — maria.gammone@istituto-besta.it
- Ospedale Universitario Luigi Sacco, Milano, Italia, Milan, Italy _(42.7824, 12.5984)_
  - Leonardo Pantoni, MD — (CONTACT) — + 39 02.2394 — leonardo.pantoni@unimi.it
- Unità Parkinson e Disturbi del Movimento, Dipartimento di Neuroscienze(DNS), Università di Padova, Padova, Italia, Padova, Italy _(44.3822, 11.1426)_
  - Angelo Antonini — (CONTACT) — angelo.antonini@unipd.it
- Centro per le Malattie Neurodegenerative e l'Invecchiamento Cerebrale, Università degli Studi di Bari "Aldo Moro" presso la Pia Fondazione "Card. G. Panico", Tricase, Italia, Tricase, Italy _(39.9302, 18.3542)_
  - Daniele Urso, MD — (CONTACT) — + 39 02.2394 — daniele.urso@kcl.ac.uk
- Unità di Neurologia, Divisione Malattia di Parkinson e Disturbi del Movimento, Dipartimento di Neuroscienze, Biomedicina e Scienze del Movimento, Università di Verona, Italia, Verona, Italy _(45.4385, 10.9938)_
  - Michele Tinazzi, MD — (CONTACT) — michele.tinazzi@univr.it

---

*Canonical: https://parkinsonspathways.com/trial/NCT07316751*  
*HTML version: https://parkinsonspathways.com/trial/NCT07316751*  
*Source data: https://clinicaltrials.gov/study/NCT07316751*